Recent Stock Surge: Teva Pharmaceutical Industries has been a hot topic on social media lately, especially following its stock hitting a 52-week high. Many users are buzzing about the company’s consistent growth over multiple quarters, with some pointing to potential upcoming catalysts like new drug approvals.
Executive Share Sales: Discussions also focus on recent insider transactions, particularly a significant sale of shares by a top executive. This move has sparked mixed reactions, with some expressing concern over the timing, while others see it as a routine financial decision unrelated to company performance.
Turnaround Narrative: There’s a growing narrative around Teva’s transformation from a debt-laden firm to a potential success story. Posts highlight optimism about its strategic moves, though a few remain skeptical, questioning if the hype matches the reality.
Note: This discussion summary was generated from an AI condensation of post data.
Teva Pharmaceutical Industries Insider Trading Activity
Teva Pharmaceutical Industries insiders have traded $TEVA stock on the open market 10 times in the past 6 months. Of those trades, 1 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:
- MARK SABAG (See "Remarks") has made 0 purchases and 2 sales selling 216,892 shares for an estimated $6,230,754.
- ROBERTO MIGNONE has made 0 purchases and 2 sales selling 250,000 shares for an estimated $6,123,385.
- RICHARD DANIELL (Exec. VP, European Commercial) sold 115,468 shares for an estimated $3,311,125
- ERIC A HUGHES (See "Remarks") sold 52,742 shares for an estimated $799,436
- CHRISTINE FOX (EVP, Head of U.S. Commercial) sold 28,229 shares for an estimated $699,523
- AMIR WEISS (Chief Accounting Officer) sold 12,300 shares for an estimated $300,564
- PLACID JOVER (See "Remarks") sold 6,053 shares for an estimated $91,748
- DAVID R. MCAVOY (EVP, Chief Legal Officer) purchased 1,113 shares for an estimated $20,988
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Teva Pharmaceutical Industries Hedge Fund Activity
We have seen 256 institutional investors add shares of Teva Pharmaceutical Industries stock to their portfolio, and 298 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 33,494,254 shares (-57.6%) from their portfolio in Q3 2025, for an estimated $676,583,930
- ION ASSET MANAGEMENT LTD. removed 32,837,875 shares (-85.6%) from their portfolio in Q3 2025, for an estimated $663,325,075
- VIKING GLOBAL INVESTORS LP removed 9,149,214 shares (-78.3%) from their portfolio in Q3 2025, for an estimated $184,814,122
- SOUNDWATCH CAPITAL LLC removed 8,564,012 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $172,993,042
- ALTSHULER SHAHAM LTD added 7,443,267 shares (+871.4%) to their portfolio in Q3 2025, for an estimated $150,353,993
- WELLINGTON MANAGEMENT GROUP LLP added 6,878,304 shares (+39228.4%) to their portfolio in Q3 2025, for an estimated $138,941,740
- FARALLON CAPITAL MANAGEMENT LLC added 4,997,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $100,939,400
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Teva Pharmaceutical Industries Analyst Ratings
Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 12/16/2025
- UBS issued a "Buy" rating on 09/24/2025
To track analyst ratings and price targets for Teva Pharmaceutical Industries, check out Quiver Quantitative's $TEVA forecast page.
Teva Pharmaceutical Industries Price Targets
Multiple analysts have issued price targets for $TEVA recently. We have seen 6 analysts offer price targets for $TEVA in the last 6 months, with a median target of $33.5.
Here are some recent targets:
- Chris Schott from JP Morgan set a target price of $35.0 on 12/16/2025
- Glen Santangelo from Barclays set a target price of $35.0 on 12/09/2025
- Jason Gerberry from B of A Securities set a target price of $32.0 on 12/09/2025
- Matt Dellatorre from Goldman Sachs set a target price of $31.0 on 12/08/2025
- Louise Chen from Scotiabank set a target price of $35.0 on 12/05/2025
- Ashwani Verma from UBS set a target price of $26.0 on 09/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
